Navigation Links
Study Shows Pine Bark Naturally Reduces Osteoarthritis
Date:4/16/2008

Pycnogenol(R) lowered joint pain by 55 percent from baseline 'severe' to

moderately painful, improved physical function by 56 percent, joint stiffness by 53 percent and increased patients' mobility almost three-fold

HOBOKEN, N.J., April 16 /PRNewswire/ -- More than 20 million Americans suffer from osteoarthritis, with half a million Americans having a total joint replacement each year. A new study to be published in the April 2008 edition (Volume 22, issue No 4) of the journal of Phytotherapy Research shows Pycnogenol(R) (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, was shown to reduce all osteoarthritis symptoms by 56 percent. The study revealed a particularly high efficacy of Pycnogenol(R) for lowering joint pain by 55 percent. Moreover, patients required dramatically less standard pain medication (-58 percent), which greatly improved the gastrointestinal complications resulting from the pain medication by 63 percent.

"Pycnogenol(R) seemed a natural fit for this study," said Dr. Gianni Belcaro, a lead researcher of the study. "There are a few main components contributing to the clinical picture of treatment management in osteoarthritis: inflammation causing a progression in the disease, alteration of fatigue resistance and muscular performance -- reversing and blocking the vascular problems associated to altered mobility. Theoretically, a treatment with a compound specifically active on all those aspects could be highly effective, which is why we chose Pycnogenol(R)."

The randomized, double-blind, placebo-controlled study, held at Italy's Chieti-Pescara University, sampled 156 patients with osteoarthritis of the knee (OA). Patients were administered 100 mg Pycnogenol(R) or placebo, daily for three months. Symptoms were evaluated by WOMAC index scores and mobility by recording their walking performance on a treadmill. Patients were permitted to continue taking their choice of pain medication provided they recorded every tablet in a diary for later evaluation.

To describe and rate osteoarthritis symptoms (joint pain, stiffness and physical function), WOMAC questionnaires were evaluated by the investigator and patient at the start and after three months of treatment. Patients were trained on a treadmill test and performance evaluation was recorded on total distance that could be covered without pain. Measuring foot volume by the water-displacement method was used to evaluate ankle/foot edema in a randomly selected subgroup of subjects within the two treatment groups.

After three months, scores for pain dropped significantly for the Pycnogenol(R) treatment group and no significant effects were recorded for the placebo group. Scores for stiffness were reduced by 53 percent. The scores for physical function were reduced by 57 percent in the Pycnogenol(R) group and improvement under placebo was not significant. The global WOMAC score decreased following Pycnogenol(R) treatment and very little in the placebo group, from 56 percent vs. 9.6 percent for Pycnogenol(R) and placebo, respectively. Overall well-being of patients (emotional function) was significantly enhanced with the Pycnogenol(R) group, by 64 percent and 15 percent for the placebo group.

Results of exercise tests on the treadmill demonstrated an increased performance after three months of Pycnogenol(R) treatment. At the start of the study, patients could only walk a mean of 74 yards without feeling pain and after three months, they could walk 216 yards, compared to the placebo group that noted 71 yards at the beginning of the study and 96 yards at the end.

In addition to the osteoarthritis results, 76 percent of the patients in the Pycnogenol(R) group and 79 percent in the placebo group showed visible ankle and foot edema at inclusion of the study. After the three months, edema decreased in 79 percent of the Pycnogenol(R) patients and only one percent in placebo-treated patients.

Patients were allowed to use their regular dosage of NSAIDS. Usage dropped by 58 percent during treatment with Pycnogenol(R) and one percent with the placebo. Evaluation of data demonstrated a decrease of gastrointestinal complications of 64 percent in the Pycnogenol(R) group versus three percent in placebo.

"The results of this study are significant as they clearly demonstrate the clinical action of Pycnogenol(R) on OA and management of symptoms. The use of Pycnogenol(R) many reduce costs and side effects of anti-inflammatory agents and offer a natural alternative solution to people suffering from OA," said Dr. Belcaro.

A previous study on osteoarthritis which was carried out at the University of Arizona Tucson (published in Nutrition Research) had discovered that Pycnogenol(R) was effective for improving pain and joint function. After three months in the Pycnogenol(R) group, there was a reduction of 43 percent in pain, 35 percent in stiffness, 52 percent in physical function subscales, respectively. The placebo group showed no significant scores throughout the entire study. Dr. Belcaro confirms this earlier study with a much larger number of patients and with a more detailed investigation procedure.

The benefits of Pycnogenol(R) for arthritic joints are suggested to result predominantly from the anti-inflammatory potency of Pycnogenol(R) which was demonstrated in a series of clinical investigations in the past. There are more breakthrough studies on Pycnogenol(R) and osteoarthritis expected to be published next year allowing for development of innovative, natural formulas for joint health. Additionally, Horphag Research, the exclusive worldwide distributor of Pycnogenol(R) has filed for several patents for Pycnogenol's(R) application for COX-1, COX-2 and treating osteoarthritis.

"The new research in the field of osteoarthritis has been a paradigm shift for Pycnogenol(R). We were able to demonstrate Pycnogenol's(R) impact on all inflammatory parameters and have succeeded in providing strong clinical evidence of Pycnogenol(R) efficacy in this field. It is obvious that Pycnogenol(R) will have to be considered as an innovative ingredient of choice for the joint health market," said Victor Ferrari, CEO of Horphag Research, the exclusive worldwide supplier of Pycnogenol(R).

B-Roll Available

Satellite Coordinates

THURSDAY, APRIL 17, 2008/10:00-10:15 AM ET & 2:00-2:15 PM ET

GALAXY 26 TRANSPONDER 1 (C-BAND)

DOWNLINK FREQ: 3720 (V)

About Pycnogenol(R)

Pycnogenol(R) is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol(R) is available in more than 600 dietary supplements, multi-vitamins and health products worldwide. For more information, visit http://www.pycnogenol.com.

Natural Health Science Inc. (NHS), based in Hoboken, New Jersey, is the North American distributor for Pycnogenol(R) (pic-noj-en-all) brand French maritime pine bark extract on behalf of Horphag Research. Pycnogenol(R) is a registered trademark of Horphag Research Ltd., Guernsey, and its applications are protected by U.S. patents #5,720,956 / #6,372,266 and other international patents. NHS has the exclusive rights to market and sell Pycnogenol(R) in North America and benefits from more than 35 years of scientific research assuring the safety and efficacy of Pycnogenol(R) as a dietary supplement. For more information about Pycnogenol(R) visit our Web site at http://www.pycnogenol.com.


'/>"/>
SOURCE Natural Health Science Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Study suggests too much screen time and not enough physical activity may lead to childhood obesity
2. St. Jude gene study reveals basis of anticancer drug resistance in childhood leukemia
3. UAB study shows investigational drug may treat biliary cancers
4. Study shows that high-dose, high-frequency interferon produces no additional benefit
5. Study finds media coverage of breast cancer focuses too little on prevention
6. USC study finds evidence of gender-related differences in development of colon cancer
7. New study in JCSM finds that obesity can predict upper airway obstruction amongst children
8. Study shows increase of hip and knee replacements in the US
9. Study shows decline in work disability due to rheumatoid arthritis
10. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
11. Study sheds light on deadly lung disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... OAKLAND, N.J. , June 24, 2016 /PRNewswire/ ... in the design, development and manufacturing of collagen ... and regeneration announced today that Bill Messer ... Sales and Marketing to further leverage the growing ... surgery medical devices. Bill joins the ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: